AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Back to Jobs

Initial focus on GJB2, the most common cause of genetic hearing loss in newborns   GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of

Apply Now